Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrabotulinumtoxinA-xvfs Microtox for Facial Skin Quality
NCT06604832Phase 1Completed
- Start
- Sep 2024
- Primary completion
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in rhytides comparing Jeuveau + Placebo with Jeuveau + Xeomin (2 arms). Primary endpoints: Scientific Assessment Scale of Skin Quality at 12 weeks and Global Aesthetic Improvement Scale at 12 weeks. Started Sep 2024; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
rhytides
Beyond the preview
Go deeper on NCT06604832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06604832.